I like to think I have a nose for news. And, some might say, too much of a penchant for puns and alliteration. Impotence drug profits won't be going up big pharma's nose. The tiny New Jersey-based biotech company Palatin Technologies says it's giving up on its experimental nasal spray for erectile dysfunction.
Cramer makes the call on viewers' favorite stocks.
The morning after Amgen reported its first quarter earnings my inbox runneth over with analyst research reports on the biotech behemoth. The company beat the Street by eight cents a share. But the focus remains on the anemia drug franchise.
Some late day earnings news could spill into Thursday's session: Apple shares rose after the company reported a 36 percent increase in profits to $1.05 billion. But the company guided third quarter below Wall Street estimates...
GlaxoSmithKline is paying big in an effort to find cures for diseases of aging. They are buying Sirtris Pharmaceuticals for $720M in cash, or $22.50/share. This price represents an 84% premium over SIRT's closing price yesterday. Two things are going on here...
Schering-Plough beat the Street by a surprising 16 cents per share and the beaten-down shares are rallying. In an exclusive CNBC interview Wednesday morning, Chairman and CEO Fred Hassan explained how the company was able to blow away estimates...
Futures about flat as oil is at least down a bit this morning. Earnings were mixed, and an IPO pricing was a bit disappointing. Boeing better than expected. ... How much money can an airline lose? Delta lost $6.4 billion, or $16.15 a share; its merger partner Northwest reported a net loss of $4.1 billion, or $15.78 a share...
GlaxoSmithKline’s profit fell 5 percent in the first quarter, hit by falling sales of diabetes drug Avandia and generic competition to other products, the world's second biggest drugmaker said.
In Tuesday’s Web Extra the traders reveal how they’re playing Pharma after Wyeth shares traded lower despite stronger-than-expected earnings. Also get the traders’ Lockheed play.
Europe's two biggest casualties from the subprime crisis tomorrow face shareholders who will want answers on how, between them, the two banking giants lost well over $50 billion.
GlaxoSmithKline said it had agreed to buy biotechnology company Sirtris Pharmaceuticals for $720 million in cash, in hopes its medicines that modulate an aging-related family of enzymes will be effective against a wide range of diseases.
This halftime report is not brought to you by (pick your prescription drug). So, we're pretty much at the midway point of big pharma's earnings season and Goldman Sachs analyst James Kelly is sizing things up so far...
The Dow pulled back Monday after a weaker-than-expected profit report from Bank of America stirred concerns about the health of corporate earnings. What's the "Word on The Street?"
The irreverent producers of "Squawk on the Street" who are stationed in the pod next to mine here at CNBC like to call it "Pharmapalooza." They're referring to weeks like the one coming up when nearly every big drug company reports earnings.
Roche Holding missed forecasts with a meagre 2 percent increase in first-quarter sales in local currencies, hit by plunging Tamiflu revenue and a slowing pace of growth for cancer drugs.
After navigating what has to be one of the most frustrating paths to Food and Drug Administration approval of a new drug, the small biopharma company Pozen and its big pharma partner GlaxoSmithKline have finally emerged victorious.
Genentech stock is on a tear this year and analysts are expecting double-digit sales growth for most of the biotech's key drugs this quarter. Can Genentech keep it up?
Last night while on the elliptical and watching "NBC Nightly News," one spot amid the wall-to-wall commercials for drugs caught my attention. It looks like after 10 years since the first erectile dysfunction pill came on the market--Pfizer's Viagra celebrated a decade since winning FDA approval last week--the makers of Levitra are trying a new marketing tack.
A drug commonly used to fight AIDS appears to nearly double the risk of a heart attack, researchers said Tuesday.
Shares of Canada's biggest biotech initially hit a new intra-day low this morning of 10 bucks a share this morning, but rallied into the close as investors seem to like the fact that the company may have extricated itself from allegations of financial fraud.